202 related articles for article (PubMed ID: 33627416)
21. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Sands E; Kivitz A; DeHaan W; Leung SS; Johnston L; Kishimoto TK
Nat Commun; 2022 Jan; 13(1):272. PubMed ID: 35022448
[TBL] [Abstract][Full Text] [Related]
22. Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia.
Monahan PE; Négrier C; Tarantino M; Valentino LA; Mingozzi F
J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199563
[TBL] [Abstract][Full Text] [Related]
23. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
[TBL] [Abstract][Full Text] [Related]
24. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
[TBL] [Abstract][Full Text] [Related]
25. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
Vandamme C; Adjali O; Mingozzi F
Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
[TBL] [Abstract][Full Text] [Related]
26. Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application.
Jacobs F; Wang L
Curr Pharm Des; 2011; 17(24):2500-15. PubMed ID: 21774772
[TBL] [Abstract][Full Text] [Related]
27. Hybrid adeno-associated viral vectors utilizing transposase-mediated somatic integration for stable transgene expression in human cells.
Zhang W; Solanki M; Müther N; Ebel M; Wang J; Sun C; Izsvak Z; Ehrhardt A
PLoS One; 2013; 8(10):e76771. PubMed ID: 24116154
[TBL] [Abstract][Full Text] [Related]
28. JSRV Intragenic Enhancer Element Increases Expression from a Heterologous Promoter and Promotes High Level AAV-mediated Transgene Expression in the Lung and Liver of Mice.
Yu DL; Chow N; Wootton SK
Viruses; 2020 Nov; 12(11):. PubMed ID: 33172105
[TBL] [Abstract][Full Text] [Related]
29. Immune Response Mechanisms against AAV Vectors in Animal Models.
Martino AT; Markusic DM
Mol Ther Methods Clin Dev; 2020 Jun; 17():198-208. PubMed ID: 31970198
[TBL] [Abstract][Full Text] [Related]
30. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver.
Qiao C; Yuan Z; Li J; He B; Zheng H; Mayer C; Li J; Xiao X
Gene Ther; 2011 Apr; 18(4):403-10. PubMed ID: 21150938
[TBL] [Abstract][Full Text] [Related]
31. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
[TBL] [Abstract][Full Text] [Related]
32. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
Zhu J; Huang X; Yang Y
J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
[TBL] [Abstract][Full Text] [Related]
33. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.
Heister T; Heid I; Ackermann M; Fraefel C
J Virol; 2002 Jul; 76(14):7163-73. PubMed ID: 12072516
[TBL] [Abstract][Full Text] [Related]
34. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.
Jayandharan GR; Zhong L; Sack BK; Rivers AE; Li M; Li B; Herzog RW; Srivastava A
Hum Gene Ther; 2010 Mar; 21(3):271-83. PubMed ID: 19788390
[TBL] [Abstract][Full Text] [Related]
35. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
[TBL] [Abstract][Full Text] [Related]
36. CpG-depleted adeno-associated virus vectors evade immune detection.
Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
[TBL] [Abstract][Full Text] [Related]
37. Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer.
Selot R; Arumugam S; Mary B; Cheemadan S; Jayandharan GR
Front Pharmacol; 2017; 8():441. PubMed ID: 28769791
[TBL] [Abstract][Full Text] [Related]
38. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
Fraefel C; Jacoby DR; Lage C; Hilderbrand H; Chou JY; Alt FW; Breakefield XO; Majzoub JA
Mol Med; 1997 Dec; 3(12):813-25. PubMed ID: 9440115
[TBL] [Abstract][Full Text] [Related]
39. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.
Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM
Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426
[TBL] [Abstract][Full Text] [Related]
40. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
